These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33383444)

  • 21. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
    Avanzi MP; Yeku O; Li X; Wijewarnasuriya DP; van Leeuwen DG; Cheung K; Park H; Purdon TJ; Daniyan AF; Spitzer MH; Brentjens RJ
    Cell Rep; 2018 May; 23(7):2130-2141. PubMed ID: 29768210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
    Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
    Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
    Gonzalez VD; Huang YW; Delgado-Gonzalez A; Chen SY; Donoso K; Sachs K; Gentles AJ; Allard GM; Kolahi KS; Howitt BE; Porpiglia E; Fantl WJ
    Cell Rep; 2021 Aug; 36(9):109632. PubMed ID: 34469729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
    Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD
    Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
    Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
    J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-33 in Malignancies: Friends or Foes?
    Shen JX; Liu J; Zhang GJ
    Front Immunol; 2018; 9():3051. PubMed ID: 30619376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
    Patton JT; Lustberg ME; Lozanski G; Garman SL; Towns WH; Drohan CM; Lehman A; Zhang X; Bolon B; Pan L; Kinghorn AD; Grever MR; Lucas DM; Baiocchi RA
    Oncotarget; 2015 Feb; 6(5):2693-708. PubMed ID: 25393910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
    Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
    Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2 regulates tumor-reactive CD8
    Liu Y; Zhou N; Zhou L; Wang J; Zhou Y; Zhang T; Fang Y; Deng J; Gao Y; Liang X; Lv J; Wang Z; Xie J; Xue Y; Zhang H; Ma J; Tang K; Fang Y; Cheng F; Zhang C; Dong B; Zhao Y; Yuan P; Gao Q; Zhang H; Xiao-Feng Qin F; Huang B
    Nat Immunol; 2021 Mar; 22(3):358-369. PubMed ID: 33432230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
    Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
    Kim K; Yang WH; Jung YS; Cha JH
    BMB Rep; 2020 Nov; 53(10):512-520. PubMed ID: 32731915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.
    Andreone S; Gambardella AR; Mancini J; Loffredo S; Marcella S; La Sorsa V; Varricchi G; Schiavoni G; Mattei F
    Front Immunol; 2020; 11():571593. PubMed ID: 33329534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.